BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21570434)

  • 1. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
    Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
    Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
    Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
    Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
    Carmon L; Avivi I; Kovjazin R; Zuckerman T; Dray L; Gatt ME; Or R; Shapira MY
    Br J Haematol; 2015 Apr; 169(1):44-56. PubMed ID: 25496030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.
    Wright SE; Rewers-Felkins KA; Quinlin IS; Fogler WE; Phillips CA; Townsend M; Robinson W; Philip R
    Immunol Invest; 2008; 37(3):215-25. PubMed ID: 18389441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
    Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
    Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy.
    Kovjazin R; Horn G; Smorodinsky NI; Shapira MY; Carmon L
    PLoS One; 2014; 9(1):e85400. PubMed ID: 24416403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
    Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
    Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
    Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
    Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model.
    Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Tezuka N; Sawai S; Inoue S; Fujino S; Maeda T; Itoh Y; Ogasawara K; Sato H; Ohkubo I; Kudo T
    Cancer Gene Ther; 2002 Apr; 9(4):330-7. PubMed ID: 11960283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
    Shi FF; Gunn GR; Snyder LA; Goletz TJ
    Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.